Adam Nelson
Psychiatry · Mill Valley, CANPI 1124032230
Payments from drug & device makers
Across 165 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$815
- Sunovion Pharmaceuticals Inc.$449
- Axsome Therapeutics, Inc.$407
- Otsuka America Pharmaceutical, Inc.$195
- plus $865 from 8 others
What the payments were for
- Consulting fees$1754%
- Food & beverage$4,78496%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $1,194 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $1,034 |
| Neurocrine Biosciences, Inc. | 20 | $815 |
| Sunovion Pharmaceuticals Inc. | 15 | $449 |
| Axsome Therapeutics, Inc. | 8 | $407 |
| Otsuka America Pharmaceutical, Inc. | 6 | $195 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $175 |
| Alkermes, Inc. | 3 | $161 |
| E.r. Squibb & Sons, L.L.C. | 2 | $156 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $89 |
| Johnson & Johnson | 3 | $58 |
| Bausch Health US, LLC | 3 | $54 |
| Lundbeck LLC | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,959 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClozarilClozapine | 13 | $18,763 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $14,902 |
| TrintellixVortioxetine Hydrobromide | 20 | $14,011 |
| Quetiapine Fumarate | 11 | $1,097 |
| Vilazodone Hcl | 19 | $858 |
| Bupropion XlBupropion Hcl | 50 | $837 |
| Olanzapine | 25 | $782 |
| Aripiprazole | 13 | $560 |
| Clozapine | 13 | $548 |
| Mirtazapine | 16 | $380 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $311 |
| Sertraline Hcl | 20 | $303 |
| Clonazepam | 18 | $264 |
| Lamotrigine | 19 | $222 |
| Fluoxetine Hcl | 16 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $407 | $14,90214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $89 | $14,01120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Mill Valley
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.